Abacavir/lamivudine plus rilpivirine is an effective and safe strategy for HIV-1 suppressed patients: 48 week results of the SIMRIKI retrospective study

  1. Troya, J.
  2. Ryan, P.
  3. Ribera, E.
  4. Podzamczer, D.
  5. Hontañón, V.
  6. Terrón, J.A.
  7. Boix, V.
  8. Moreno, S.
  9. Barrufet, P.
  10. Castaño, M.
  11. Carrero, A.
  12. Galindo, M.J.
  13. Suárez-Lozano, I.
  14. Knobel, H.
  15. Raffo, M.
  16. Solõs, J.
  17. Yllescas, M.
  18. Esteban, H.
  19. González-Garcõa, J.
  20. Berenguer, J.
  21. Imaz, A.
Aldizkaria:
PLoS ONE

ISSN: 1932-6203

Argitalpen urtea: 2016

Alea: 11

Zenbakia: 10

Mota: Artikulua

DOI: 10.1371/JOURNAL.PONE.0164455 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus